RaQualia grants Meiji Seika exclusive Japanese rights to develop and commercialize second generation antipsychotic ziprasidone

RaQualia Pharma Inc.

Japan / Small-Cap Biopharma (<$1 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Meiji Seika Kaisha Ltd.

Japan / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced